Blood Stream Infections
1
Pipeline Programs
5
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
5 companies ranked by most advanced pipeline stage
MSDIreland - Ballydine
1 programClinical Outcomes in Candidemia Patients Based on in Vitro SusceptibilityN/A
Sharp TherapeuticsPA - Pittsburgh
1 programClinical Outcomes in Candidemia Patients Based on in Vitro SusceptibilityN/A1 trial
Active Trials
Merck & Co.RAHWAY, NJ
1 programClinical Outcomes in Candidemia Patients Based on in Vitro SusceptibilityN/A
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
bioMerieuxRapid Diagnostics
Sharp TherapeuticsClinical Outcomes in Candidemia Patients Based on in Vitro Susceptibility
Clinical Trials (2)
Total enrollment: 2,350 patients across 2 trials
EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics
Start: Dec 2023Est. completion: Dec 20261,900 patients
Phase 4Recruiting
NCT01077336Sharp TherapeuticsClinical Outcomes in Candidemia Patients Based on in Vitro Susceptibility
Clinical Outcomes in Candidemia Patients Based on in Vitro Susceptibility
Start: Jan 2010Est. completion: Jan 2011450 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 2,350 patients
5 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.